oncology
Lung Cancer

PBS listing for ROS-1 positive NSCLC therapy

The ROS1 inhibitor entrectinib has been listed on the PBS for the treatment of patients with ROS-1 positive NSCLC. From 1 August, Roche’s entrectinib will be subsidised for patients with locally advanced (Stage IIIB) or metastatic (Stage IV)  non-small cell lung cancer (NSCLC) patients with a c-ROS proto-oncogene 1 (ROS1) gene rearrangement. Treatment eligibility is ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic